Detalles de la búsqueda
1.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
N Engl J Med;
2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38739079
2.
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
J Card Fail;
2024 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38215932
3.
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF.
J Card Fail;
30(1): 26-35, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37683911
4.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
J Card Fail;
2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493832
5.
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Eur Heart J;
43(23): 2212-2220, 2022 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35325102
6.
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
Eur Heart J;
43(48): 5006-5016, 2022 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35675469
7.
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
JAMA;
328(3): 259-269, 2022 07 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35852527
8.
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Circulation;
135(20): 1911-1921, 2017 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28246236
9.
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
J Card Fail;
29(11): 1576-1582, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37473912
10.
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Diabetes Obes Metab;
19(5): 664-671, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28058763
11.
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Lancet;
385(9982): 2067-76, 2015 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25765696
12.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
N Engl J Med;
369(14): 1327-35, 2013 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23992602
13.
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
Am Heart J;
175: 18-27, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179720
14.
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators.
Am Heart J;
169(3): 305-14, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25728719
15.
Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.
Heart Fail Rev;
20(4): 393-400, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25894076
16.
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Amyotroph Lateral Scler Frontotemporal Degener;
25(1-2): 162-169, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37641579
17.
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction.
JACC Heart Fail;
12(3): 552-563, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38300212
18.
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
JACC Heart Fail;
12(1): 199-215, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38032573
19.
Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives.
Heart Fail Clin;
9(3): 285-90, v-vi, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23809415
20.
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial.
Eur J Heart Fail;
25(2): 248-259, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36597719